The film produced entirely with artificial intelligence positions Spanish filmmaker Daniel H. Torrado as a pioneer in a new era of cinema.

CANNES, France, May 23, 2025 /PRNewswire/ — Following its screening at the European Film Market of the Berlin International Film Festival (Berlinale) last February, the apocalyptic sci-fi thriller ‘The Great Reset’ has been presented at the Cannes Film Festival’s Marché du Film. It is the first time that a feature film created with artificial intelligence (AI) has been presented at the world’s leading professional film market, where it has aroused significant interest among distributors and specialised media.

The work, written and directed by award-winning filmmaker Daniel H. Torrado, is both a narrative and technological milestone and positions the Spanish filmmaker as a pioneer in a new era of cinema.

The innovative impact of ‘The Great Reset’ has been recognised by the prestigious specialist magazine The Hollywood Reporter, which dedicated in its special edition on the Cannes Film Festival an article entitled ‘Spain tests the waters of artificial intelligence’. The article highlights the pioneering role of the film and especially Torrado’s participation in the advances of artificial intelligence in the audiovisual field.

It is a production of the companies Virtual World Pictures and Canary Film Factory.

The project began in 2023 with the writing of the script. Over the last year, the AI workflow has been designed and optimised, including fine-tuning of the models, to ensure full control over the creativity of the material generated. Although the entire film was computer generated, and all sets and characters were created digitally, some scenes used actors as reference for acting and dubbing.

AI was involved in all stages of production and post-production, from image and animation generation to sound design, but always with human supervision.

“We are very proud to present The Great Reset at the Cannes Film Festival’s Marché du Film, a space where the most innovative ideas in contemporary cinema converge. It will undoubtedly be a key impulse to introduce the world to this story that explores not only the narrative potential of AI, but also its ability to transform the film industry,” said Torrado.

In the film, an artificial intelligence, created from the mind of an unscrupulous hacker, sets in motion an apocalyptic plan to destroy the world in order to save the only person he has ever loved: his daughter. Faced with the collapse of humanity and the echoes of a broken past, Emma embarks on a desperate race to save the world.

Trailer: https://vimeo.com/1082697453/30033a63b9

Media Contact:
Jose Hernandez, Virtual World Pictures
***@virtualworldpictures.com
+34 604 96 44 72

Photos:
https://www.prlog.org/13076582

Press release distributed by PRLog

View original content:https://www.prnewswire.com/news-releases/the-great-reset-the-first-photorealistic-ai-film-makes-history-at-the-cannes-film-festival-302464613.html

SOURCE Virtual World Pictures

VANCOUVER, BC, May 23, 2025 /CNW/ — GreenPower Motor Company Inc. (NASDAQ: GP) (TSXV: GPV) (the “Company”), a leading manufacturer and distributor of purpose-built, all-electric, zero-emission medium and heavy-duty vehicles serving the cargo and delivery market, shuttle and transit space and school bus sector, announces the results of the Annual General and Special Meeting (AGM) that was held today.

The shareholders elected all of management’s director nominees being Mark Achtemichuk, Fraser Atkinson, Malcolm Clay, Sebastian Giordano, David Richardson and Brendan Riley.

The shareholders also re-approved the Company’s 2022 Equity Incentive Plan and appointed BDO Canada LLP as the Company’s auditors for the ensuing fiscal year.

Following the AGM the Directors of the Company appointed the following officers of the Company for the ensuing year:  Fraser Atkinson – Chairman and Chief Executive Officer, Brendan Riley – President and Michael Sieffert – Chief Financial Officer and Corporate Secretary.

Contact

Fraser Atkinson, CEO 
(604) 220-8048

About GreenPower Motor Company Inc.
GreenPower designs, builds and distributes a full suite of high-floor and low-floor all-electric medium and heavy-duty vehicles, including transit buses, school buses, shuttles, cargo vans and a cab and chassis. GreenPower employs a clean-sheet design to manufacture all-electric vehicles that are purpose-built to be battery powered with zero emissions while integrating global suppliers for key components. This OEM platform allows GreenPower to meet the specifications of various operators while providing standard parts for ease of maintenance and accessibility for warranty requirements. GreenPower was founded in Vancouver, Canada with primary operational facilities in southern California. Listed on the Toronto exchange since November 2015, GreenPower completed its U.S. IPO and NASDAQ listing in August 2020. For further information go to www.greenpowermotor.com.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. © 2025 GreenPower Motor Company Inc. All rights reserved.

View original content to download multimedia:https://www.prnewswire.com/news-releases/greenpower-announces-results-of-annual-general-and-special-meeting-and-appointment-of-officers-302464626.html

SOURCE GreenPower Motor Company

IRVING, Texas, May 23, 2025 /PRNewswire/ — Caris Life Sciences® (“Caris”), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to a proposed initial public offering of its Class A common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. Caris has applied to list its Class A common stock on the Nasdaq Global Select Market under the ticker symbol “CAI.”

BofA Securities, J.P. Morgan and Goldman Sachs & Co. LLC will act as lead book-running managers for the proposed offering. Citigroup will also act as a book-running manager for the proposed offering. TD Cowen, Evercore ISI and Guggenheim Securities will act as additional book-running managers for the proposed offering. BTIG and Wolfe | Nomura Alliance will act as co-managers for the proposed offering.

The proposed offering will be made available only by means of a prospectus. Copies of the preliminary prospectus, when available, may be obtained from: BofA Securities, NC1-022-02-25, 201 North Tryon Street, Charlotte, North Carolina 28255, Attention: Prospectus Department or by email: dg.prospectus_requests@bofa.com; J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717 or by email: prospectus-eq_fi@jpmchase.com; or Goldman Sachs & Co. LLC, Attn: Prospectus Department, 200 West Street, New York, New York 10282 or by email: prospectus-ny@ny.email.gs.com.

A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Caris Life Sciences
Caris Life Sciences® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer that is actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced AI and machine learning algorithms at scale, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies, and high-performance computing provides a differentiated platform to develop the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development.

Caris was founded with the belief and vision that combining a vast set of consistently generated molecular information with robust data-driven insights could realize the potential of precision medicine for patients. Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S. and other international markets.

Caris Life Sciences Media:
Corporate Communications
CorpComm@CarisLS.com
214.294.5606

View original content to download multimedia:https://www.prnewswire.com/news-releases/caris-life-sciences-files-registration-statement-for-proposed-initial-public-offering-302464597.html

SOURCE Caris Life Sciences